You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

January 17, 2014

Web Version  |  Share with a colleague

Facebook Like   Twitter Tweet

Today's Headlines

Gestational diabetes: Screen at 24 weeks

All pregnant women should be screened for gestational diabetes mellitus at 24 weeks gestation, even if they have no symptoms, according to new recommendations from the U.S. Preventive Services Task Force. » Full article

The hunger-healthcare connection

Hunger in the United States may have important health consequences, including a higher risk of low blood sugar, a new study suggested. » Full article

Continuing Education

New CPE: Clinical Updates in Diabetes Care

This month, Drug Topics offers “Clinical Updates in Diabetes Care,” a knowledge-based activity worth up to 2 credits. The goal of this activity is to assist pharmacists in recognizing and understanding the changes in diabetes care to provide optimal evidence-based care for patients with diabetes. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.


Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

EDITOR'S PICK

Drugs in Context: Takeda's and Lundbeck's Brintellix

Major depressive disorder (MDD) is a medical illness that is characterized by depressed mood, hopelessness, and loss of interest.1 According to the National Institute of Mental Health, approximately 6.7% of US adult population experienced MDD, with 30.4% of these cases (2.0% of US adult population) classified as severe. » Full article

 

Related Articles

Anti-diabetic drugs can lower cancer risk by 32%

Farxiga rebounds, approved to treat type 2 diabetes

RESOURCES

Drug Watch

Latest Clinical News

 
Powered by Modern Medicine Advanstar Medical Communications Group